• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Life Sciences | News, Analysis, Insights - HIT Consultant

Alphabet’s Verily, Emory Healthcare Partner to Leverage Big Data to Optimize Medication & Lab Ordering Patterns

by Fred Pennic 12/26/2019 Leave a Comment

Alphabet’s Verily, Emory Healthcare Partner to Leverage Big Data to Optimize Medication & Lab Ordering Patterns

- Alphabet’s Verily is partnering with Atlanta, GA-based Emory Healthcare on deep analysis of medications and lab ordering patterns for improved diagnosis and treatment at the point of care. - Verily is a subsidiary of Alphabet focused on life sciences and healthcare that develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage diseaseVerily, an Alphabet company is partnering with Emory Healthcare to deploy new solutions to help
Read More

Verantos Awarded NIH Grant to Fund Clinical Phenotyping in Real-World Evidence

by Fred Pennic 12/10/2019 Leave a Comment

Verantos Awarded NIH Grant to Fund Clinical Phenotyping in Real-World Evidence

- Verantos has been awarded a grant from the National Institutes of Health (NIH) to fund advanced clinical phenotyping in real-world evidence (RWE) studies.- Grant number R44TR002437 ties directly to the 21st Century Cures Act's national goals of increasing the use of RWE to refine the standard of care and create a more tailored approach to therapy.Verantos, a Palo Alto, CA-based provider of regulatory-grade real-world evidence (RWE) studies, today announced that it has received a grant from the
Read More

Cleveland Clinic Awarded $12M to Study Link Between Gut Microbes & Heart Disease

by Jasmine Pennic 11/22/2019 Leave a Comment

Cleveland Clinic Awarded $12M to Study Gut Microbes and Heart Disease

- Stanley Hazen, M.D., Ph.D., director of Cleveland Clinic's Center for Microbiome & Human Health and his team has been awarded a $12M NIH grant to study the link between gut microbes, heart disease. - The new research program will consist of three specialized projects and four supporting cores focused on the gut microbiome. TheNational Institutes of Health (NIH) has awarded more than $12 million to Cleveland Clinic researchers to study the critical link between gut microbial pathways and
Read More

Industry 4.0 in Life Sciences: A “5C” Point of View

by Chetan Kothari, Director of Business Consulting, Life Science Division at NTT DATA Services 11/21/2019 Leave a Comment

Industry 4.0 in Life Sciences: A “5C” Point of View

McKinsey & Company describes Industry 4.0 as the next phase in the digitization of the manufacturing sector that is being driven by four disruptions: the astonishing rise in data volumes, computational power and connectivity, especially new low-power wide-area networks; the emergence of analytics and business intelligence capabilities; the new forms of human-machine interaction, such as touch interfaces and augmented reality systems; and the improvements in transferring digital instructions
Read More

GenapSys Nabs $90M to Commercialize Its Breakthrough Electronic Gene Sequencer

by Fred Pennic 11/20/2019 Leave a Comment

- GenapSys launches their first-of-its-kind electronic gene sequencer as well as the completion of a $90M series C funding round led by top biotech investor Foresite Capital. - GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size. - The GenapSys Sequencer is exceptionally accurate and 100x smaller and more affordable than current high-throughput sequencers and will significantly expand access to genetic health insights. GenapSys Inc. announced today that it has completed a $90 million funding round, led by Foresite Capital to commercialize the smallest and most affordable highly accurate sequencer ever developed. Now available for purchase, the device uses first-of-its-kind technology to deliver results at a fraction of the cost of legacy technologies, while still delivering highly accurate results. This latest investment round brings the company’s total funding to $166M to date. The new capital will be used to drive the commercial launch of the company’s first-generation product, grow GenapSys’ interdisciplinary team, and empower continued innovation. Accessible Sequencing Holds the Key to Innovation In 2019, 10 million people will die of cancer. And, yet, only 3 percent of cancer drugs tested in clinical trials since 2000 have been approved for patient use and not a single one offers a cure. Gene sequencing maybe the answer. By analyzing every component of our DNA, gene sequencing allows doctors and scientists to more effectively diagnose disease and develop better treatments. Beyond cancer, sequencing has the potential to supercharge everything from reproductive health to pathogen testing. But a single sequencing device typically costs up to $1M, limiting its reach and acting as a major bottleneck to advancement in healthcare. A Breakthrough in Sequencing with High Accuracy and Low Cost GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size miniaturized to the size of an iPad. It's up to 100x smaller and less expensive at under $10,000 than legacy sequencing technologies, while redefining the gold standard with over 99.9% accuracy. In other words, similar to the iPhone, sequencing will be taken to the size of a mobile device and made affordable to nearly any institution. For the $46B genomics market previously dominated by much more expensive device companies like Illumina, this could transform healthcare as we know it. Unlike many others on the market, GenapSys achieves gold standard accuracy while maintaining low costs and portability. An independent study conducted by The Jackson Laboratory, a leading global nonprofit biomedical research institution, found that GenapSys sequencers deliver consistent and excellent performance across a variety of biological samples. Recently at American Society of Human Genetics in Houston, The Jackson Laboratory presented the results of their study which found that the GenapSys sequencers are superior to optical detection methods in detecting single nucleotide mutations, a critical task used for cancer and inherited disease detection. Availability The GenapSys sequencer has been tested extensively across leading genomics labs across the nation. All studies thus far have indicated exceptional performance; published work is publicly available on BioRxiv. The GenapSys Sequencer is currently available for order in the U.S. with global sales beginning in early 2020. “We are entering a multi-decade era of genomics that will revolutionize many industries, including healthcare diagnostics, pharmaceutical discovery, personalized medicine, food testing, forensics, agriculture, biology and beyond - but until now, we’ve lacked the access necessary to realize this potential,” explained Dr. Hesaam Esfandyarpour, CEO and founder of GenapSys. “With our new sequencer, we can rapidly enable and scale genomics power to every researcher, physician, provider, and patient around the world.”

- GenapSys launches first-of-its-kind electronic gene sequencer as well as the completion of a $90M series C funding round led by top biotech investor Foresite Capital.  - GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size.- The GenapSys Sequencer is exceptionally accurate and 100x smaller and more affordable than current high-throughput sequencers and will significantly expand
Read More

InterSystems, Virtusa Partner to Enhance Patient Data Integration

by Jasmine Pennic 11/20/2019 Leave a Comment

InterSystems, Virtusa Partner to Enhance Patient Data Integration

- InterSystems and Virtusa Corporation partner to enhance the healthcare data integration capabilities of its vLife™ life sciences platform.- The Collaboration will create an advanced platform for healthcare data management, research and analytics.InterSystems, and Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions have announced their partnership in an effort to drive positive patient outcomes while reducing cost through improved
Read More

Life Image, Graticule Launches Imaging Dataset In AWS Data Exchange

by Fred Pennic 11/18/2019 Leave a Comment

Life Image, Graticule Launches Imaging Dataset In AWS Data Exchange

 - Life Image and Graticule announced the availability of GLIMPS (Graticule Life Image Machine Parsed Set) data licensing subscriptions in AWS Data Exchange. - GLIMPS (Graticule Life Image Machine Parsed Set) is a de-identified patient-level data set including a summary of features generated from NLP processing on Life Image data. - The goal of GLIMPS is to provide a cost-effective patient-level snapshot to biopharma data science teams to fuel the necessary discussions about these data, leading
Read More

Five Lessons Learned From Building A CRM for Pharma

by Thom Doyle, President, Human Care Systems 11/15/2019 Leave a Comment

Five Lessons Learned From Building a CRM for Pharma

We all know the pleasure of interacting with technology that does exactly what it’s designed to do. Whether it’s getting to your destination via Waze, reserving dinner through OpenTable or making an electronic payment through Venmo, applications that work have one important thing in common: they are designed with a purpose and are the true experts in getting exactly that thing done seamlessly. But professional industry software, especially when it comes to healthcare, is a lot more complex.
Read More

Vermont Health Network Launches Pilot Project to Offer Free Genetic DNA Testing

by Fred Pennic 11/07/2019 Leave a Comment

Vermont Health Network Launches Pilot Project to Offer Free Genetic DNA Testing

Key Highlights LunaPBC announces a partnership allowing patients in Vermont to donate genetic information to medical research via a partnership with the University of Vermont Health Network via Invitae. Free genetic testing is now offered to qualifying patients to identify increased risk for certain diseases. Patients can then consent to securely share their data with researchers through the LunaDNA platform. In return, patients receive shares of ownership in the company, allowing
Read More

Mission Bio Expands Into Single-Cell Multi-Omics With Platform That Detects DNA and Protein from the Same Cell

by Fred Pennic 11/06/2019 Leave a Comment

Mission Bio Expands Into Single-Cell Multi-Omics With Platform That Detects DNA and Protein from the Same Cell

Key Highlights- Mission Bio expands into single-cell multi-omics with the launch of its new proprietary technology platform. - The Tapestri Platform is the first and only to enable key insights to drive the development of more impactful cancer therapies. Mission Bio, Inc., a South San Francisco, CA-based pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company’s proprietary technology, the Tapestri
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 86
  • Go to page 87
  • Go to page 88
  • Go to page 89
  • Go to page 90
  • Interim pages omitted …
  • Go to page 92
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |